I agree that this site is using cookies. You can find further informations here.
X
Selmaj, K.
148  results:
Search for persons X
?
1

Subcutaneous Ocrelizumab in Patients with Multiple Sclerosi..:

Newsome, SD ; Krzystanek, E ; Selmaj, K...
Multiple Sclerosis and Related Disorders.  80 (2023)  - p. 105307 , 2023
Link: https://doi.org/10.1016/..
 
?
2

DOP53 Pregnancy outcomes in the ozanimod clinical developme..:

Dubinsky, M C ; Mahadevan, U ; Charles, L...
Journal of Crohn's and Colitis.  15 (2021)  Supplement_1 - p. S088-S089 , 2021
Link: https://doi.org/10.1093/..
 
?
3

ECTRIMS/EAN guideline on the pharmacological treatment of p..:

Montalban, X. ; Gold, R. ; Thompson, A. J....
European Journal of Neurology.  25 (2018)  2 - p. 215-237 , 2018
Link: https://doi.org/10.1111/..
 
?
4

P 2 Effect of ocrelizumab on humoral immunity markers in th..:

Ziemssen, T. ; Bar-Or, A. ; Arnold, D.L....
Clinical Neurophysiology.  128 (2017)  10 - p. e326-e327 , 2017
Link: https://doi.org/10.1016/..
 
?
5

P 1 Effect of ocrelizumab on magnetic resonance imaging mar..:

Ziemssen, T. ; Arnold, D.L. ; Bar-Or, A....
Clinical Neurophysiology.  128 (2017)  10 - p. e326 , 2017
Link: https://doi.org/10.1016/..
 
?
6

Induction of human IL-10-producing neutrophils by LPS-stimu..:

Lewkowicz, N ; Mycko, M P ; Przygodzka, P...
Mucosal Immunology.  9 (2016)  2 - p. 364-378 , 2016
Link: https://doi.org/10.1038/..
 
?
7

Daclizumab high‐yield process reduced the evolution of new ..:

Radue, E.‐W. ; Sprenger, T. ; Vollmer, T....
European Journal of Neurology.  23 (2016)  2 - p. 412-415 , 2016
Link: https://doi.org/10.1111/..
 
?
8

Daclizumab HYP reduces total disability burden of patients ..:

Boyko, A. ; Kappos, L. ; Rose, J....
Journal of the Neurological Sciences.  357 (2015)  - p. e300-e301 , 2015
Link: https://doi.org/10.1016/..
 
?
9

Phase 2 BOLD extension study efficacy results for siponimod..:

Stuve, O. ; Hartung, H.P. ; Freedman, M....
Multiple Sclerosis and Related Disorders.  3 (2014)  6 - p. 754-755 , 2014
Link: https://doi.org/10.1016/..
 
?
10

A randomized placebo-controlled phase III trial of oral laq..:

On behalf of the BRAVO Study Group ; Vollmer, T. L. ; Sorensen, P. S....
Journal of Neurology.  261 (2014)  4 - p. 773-783 , 2014
Link: https://doi.org/10.1007/..
 
?
11

Gastrointestinal tolerability events in relapsing–/INS;remi..:

Havrdova, E. ; Phillips, J.T. ; Selmaj, K....
Journal of the Neurological Sciences.  333 (2013)  - p. e368-e369 , 2013
Link: https://doi.org/10.1016/..
 
?
12

Safety and tolerability of BG-12 (dimethyl fumarate) in rel..:

Selmaj, K. ; Phillips, J.T. ; Fox, R.J....
Journal of the Neurological Sciences.  333 (2013)  - p. e367-e368 , 2013
Link: https://doi.org/10.1016/..
 
?
13

BG-12 Increases the Proportion of Patients Free of Clinical..:

Giovannoni, G. ; Gold, R. ; Kappos, L....
Neurology.  78 (2012)  Meeting Abstracts 1 - p. PD5.005-PD5.005 , 2012
Link: https://doi.org/10.1212/..
 
?
14

PND63 Effects of BG-12 on Quality of Life in Relapsing–Remi..:

Kappos, L. ; Gold, R. ; Arnold, D.L....
Value in Health.  15 (2012)  7 - p. A557 , 2012
Link: https://doi.org/10.1016/..
 
?
15

MRI Findings of BOLD: A Phase 2 Dose-Finding Study Using Ad..:

Li, D. ; Selmaj, K. ; Zhao, G....
Neurology.  78 (2012)  Meeting Abstracts 1 - p. S11.005-S11.005 , 2012
Link: https://doi.org/10.1212/..
 
1-15